Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection

Nature

Volumn 454, Issue 7206, 2008, Pages 894-898

  Premenko Lanier, Mary ^a   Moseley, Nelson B ^a   Pruett, Sarah T ^b   Romagnoli, Pablo A ^a   Altman, John D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT;

CYTOLOGY; DISEASE TREATMENT; IMMUNE RESPONSE; VIRAL DISEASE; VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARMSTRONG STRAIN; ARTICLE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNE RESPONSE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS STRAIN;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MUS;

EID: 49649119704     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07199     Document Type: Article

References (25)

1. Ahmed, R., Byrne, J. A. & Oldstone, M. B. Virus specificity of cytotoxic T lymphocytes generated during acute lymphocytic choriomeningitis virus infection: role of the H-2 region in determining cross-reactivity for different lymphocytic choriomeningitis virus strains. J. Virol. 51, 34-41 (1984).
2. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056-8063 (1994).
3. Kunzendorf, U., Ziegler, E. & Kabelitz, D. FTY720-the first compound of a new promising class of immunosuppressive drugs. Nephrol. Dial. Transplant. 19, 1677-1681 (2004).
4. Chisari, F. V. & Ferrari, C. Hepatitis B virus immunopathology. Springer Semin. Immunopathol. 17, 261-281 (1995).
5. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
6. Folgori, A. et al. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut 55, 1012-1019 (2006).
7. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911-4927 (2003).
8. Shiow, L. R. et al. CD69 acts downstream of interferon-α/ β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440, 540-544 (2006).
9. Mamalaki, C. et al. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 3, 159-174 (1993).
10. Brinkmann, V. et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453-21457 (2002).
11. Chiba, K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108, 308-319 (2005).
12. Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124-1140 (2006).
13. Budde, K. et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13, 1073-1083 (2002).
14. Pinschewer, D. D. et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164, 5761-5770 (2000).
15. Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758-761 (1993).
16. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
17. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
18. Brooks, D. G. et al. Interleukin-10 determines viral clearance or persistence in vivo. Nature Med. 12, 1301-1309 (2006).
19. Matter, M., Odermatt, B., Yagita, H., Nuoffer, J. M.&Ochsenbein, A. F. Elimination of chronic viral infection by blocking CD27 signaling. J. Exp. Med. 203, 2145-2155 (2006).
20. Brooks, D. G., Lee, A. M., Elsaesser, H., McGavern, D. B. & Oldstone, M. B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 205, 533-541 (2008).
21. Ha, S. J. et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 205, 543-555 (2008).
22. Muller, S. et al. Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production. J. Virol. 76, 2375-2383 (2002).
23. Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
24. Cembrzynska-Nowak, M. Different antiviral activity and cell specificity of interferon preparations produced by mouse peritoneal cells at 37 degrees C and at 26 degrees C. Arch. Immunol. Ther. Exp. (Warsz.) 37, 499-502 (1989).
25. Merrill, A. H. Jr, Sullards, M. C., Allegood, J. C., Kelly, S. & Wang, E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36, 207-224 (2005).